TRADES
Latest Trades
3142
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 12 Aug 2022 Buy FATE FATE THERAPEUTICS INC 1,004 0.0011
ARKG 12 Aug 2022 Sell CGEN COMPUGEN LTD 369,531 0.0180
ARKG 11 Aug 2022 Buy TDOC TELADOC INC 21,304 0.0256
ARKG 11 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 23,651 0.0059
ARKG 11 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 493,220 0.2668
ARKG 11 Aug 2022 Buy FATE FATE THERAPEUTICS INC 149,304 0.1547
ARKG 11 Aug 2022 Sell CGEN COMPUGEN LTD 434,497 0.0211
ARKG 10 Aug 2022 Buy TDOC TELADOC INC 975 0.0012
ARKG 10 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 144,657 0.0369
ARKG 10 Aug 2022 Sell CGEN COMPUGEN LTD 84,896 0.0043
ARKG 9 Aug 2022 Buy TDOC TELADOC INC 27,254 0.0312
ARKG 9 Aug 2022 Buy SDGR SCHRODINGER INC 10,545 0.0106
ARKG 9 Aug 2022 Buy PSNL PERSONALIS INC 111,910 0.0147
ARKG 9 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 140,099 0.0753
ARKG 9 Aug 2022 Sell CGEN COMPUGEN LTD 31,857 0.0015
ARKG 8 Aug 2022 Sell TWST TWIST BIOSCIENCE CORP 55,495 0.1005
ARKG 8 Aug 2022 Buy TDOC TELADOC INC 44,228 0.0558
ARKG 8 Aug 2022 Buy SDGR SCHRODINGER INC 168,668 0.1826
ARKG 8 Aug 2022 Buy PSNL PERSONALIS INC 15,296 0.0022
ARKG 8 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 134,667 0.0740
ARKG 8 Aug 2022 Buy NVTA INVITAE CORP 186,884 0.0155
ARKG 8 Aug 2022 Sell CGEN COMPUGEN LTD 22,341 0.0011
ARKG 5 Aug 2022 Buy SDGR SCHRODINGER INC 57,047 0.0613
ARKG 5 Aug 2022 Buy PSNL PERSONALIS INC 100,000 0.0140
ARKG 5 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 180,096 0.1013
ARKG 4 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 98,284 0.0192
ARKG 4 Aug 2022 Sell CGEN COMPUGEN LTD 35,594 0.0019
ARKG 3 Aug 2022 Sell CGEN COMPUGEN LTD 74,934 0.0043
ARKG 2 Aug 2022 Buy TDOC TELADOC INC 16,018 0.0210
ARKG 2 Aug 2022 Buy RXRX RECURSION PHARMACEUTICALS 25,000 0.0077
ARKG 2 Aug 2022 Sell CGEN COMPUGEN LTD 16,561 0.0010
ARKG 1 Aug 2022 Buy RXRX RECURSION PHARMACEUTICALS 28,587 0.0085
ARKG 1 Aug 2022 Buy PSNL PERSONALIS INC 21,911 0.0028
ARKG 1 Aug 2022 Buy NRIX NURIX THERAPEUTICS INC 600 0.0003
ARKG 1 Aug 2022 Sell CGEN COMPUGEN LTD 13,067 0.0008
ARKG 29 Jul 2022 Buy TXG 10X GENOMICS INC 18,029 0.0247
ARKG 29 Jul 2022 Buy SDGR SCHRODINGER INC 15,468 0.0172
ARKG 29 Jul 2022 Buy RXRX RECURSION PHARMACEUTICALS 9,193 0.0026
ARKG 29 Jul 2022 Buy PSNL PERSONALIS INC 48,061 0.0061
ARKG 29 Jul 2022 Sell ONEM 1LIFE HEALTHCARE INC 91,416 0.0543
ARKG 29 Jul 2022 Buy NRIX NURIX THERAPEUTICS INC 1,466 0.0008
ARKG 29 Jul 2022 Buy GH GUARDANT HEALTH INC 50,008 0.0883
ARKG 29 Jul 2022 Buy CDNA CAREDX INC 123,815 0.1043
ARKG 29 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 72,041 0.0099
ARKG 28 Jul 2022 Buy TXG 10X GENOMICS INC 13,455 0.0176
ARKG 28 Jul 2022 Buy TDOC TELADOC INC 84,106 0.1025
ARKG 28 Jul 2022 Buy SDGR SCHRODINGER INC 59,591 0.0652
ARKG 28 Jul 2022 Buy RXRX RECURSION PHARMACEUTICALS 25,956 0.0072
ARKG 28 Jul 2022 Buy PSNL PERSONALIS INC 105,500 0.0136
ARKG 28 Jul 2022 Sell ONEM 1LIFE HEALTHCARE INC 560,370 0.3268
ARKG 28 Jul 2022 Buy GH GUARDANT HEALTH INC 23,474 0.0403
ARKG 28 Jul 2022 Buy EXAS EXACT SCIENCES CORP 23,682 0.0374
ARKG 28 Jul 2022 Sell CGEN COMPUGEN LTD 7,292 0.0004
ARKG 28 Jul 2022 Buy CDNA CAREDX INC 57,014 0.0471
ARKG 28 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 340,015 0.0451
ARKG 27 Jul 2022 Buy TXG 10X GENOMICS INC 10,100 0.0132
ARKG 27 Jul 2022 Buy SDGR SCHRODINGER INC 42,001 0.0475
ARKG 27 Jul 2022 Buy RXRX RECURSION PHARMACEUTICALS 87,839 0.0248
ARKG 27 Jul 2022 Sell ONEM 1LIFE HEALTHCARE INC 1,014,464 0.6085
ARKG 27 Jul 2022 Buy GH GUARDANT HEALTH INC 68,974 0.1194
ARKG 27 Jul 2022 Buy EXAS EXACT SCIENCES CORP 27,307 0.0444
ARKG 27 Jul 2022 Sell CGEN COMPUGEN LTD 38,038 0.0023
ARKG 27 Jul 2022 Buy CDNA CAREDX INC 54,072 0.0454
ARKG 27 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 150,000 0.0201
ARKG 26 Jul 2022 Buy TXG 10X GENOMICS INC 25,156 0.0306
ARKG 26 Jul 2022 Buy SDGR SCHRODINGER INC 44,618 0.0490
ARKG 26 Jul 2022 Buy RXRX RECURSION PHARMACEUTICALS 30,355 0.0083
ARKG 26 Jul 2022 Sell ONEM 1LIFE HEALTHCARE INC 1,515,845 0.8940
ARKG 26 Jul 2022 Buy GH GUARDANT HEALTH INC 347,683 0.5883
ARKG 26 Jul 2022 Buy EXAS EXACT SCIENCES CORP 75,780 0.1196
ARKG 26 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 567,281 0.0521
ARKG 26 Jul 2022 Buy CDNA CAREDX INC 22,214 0.0180
ARKG 26 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 265,580 0.0338
ARKG 25 Jul 2022 Buy TXG 10X GENOMICS INC 47,228 0.0568
ARKG 25 Jul 2022 Buy SDGR SCHRODINGER INC 62,549 0.0673
ARKG 25 Jul 2022 Buy RXRX RECURSION PHARMACEUTICALS 23,200 0.0061
ARKG 25 Jul 2022 Sell ONEM 1LIFE HEALTHCARE INC 750,000 0.4366
ARKG 25 Jul 2022 Buy GH GUARDANT HEALTH INC 81,105 0.1362
ARKG 25 Jul 2022 Buy EXAS EXACT SCIENCES CORP 124,829 0.1939
ARKG 25 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 444,611 0.0419
ARKG 25 Jul 2022 Buy CDNA CAREDX INC 37,018 0.0294
ARKG 25 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 266,646 0.0342
ARKG 22 Jul 2022 Buy ZY ZYMERGEN INC 449,469 0.0289
ARKG 22 Jul 2022 Sell CGEN COMPUGEN LTD 31,270 0.0021
ARKG 22 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 447,539 0.0573
ARKG 21 Jul 2022 Buy ZY ZYMERGEN INC 77,451 0.0055
ARKG 20 Jul 2022 Buy ZY ZYMERGEN INC 51,204 0.0037
ARKG 20 Jul 2022 Sell CGEN COMPUGEN LTD 130,504 0.0087
ARKG 19 Jul 2022 Buy ZY ZYMERGEN INC 214,204 0.0157
ARKG 19 Jul 2022 Buy NRIX NURIX THERAPEUTICS INC 321 0.0002
ARKG 19 Jul 2022 Sell CGEN COMPUGEN LTD 53,303 0.0037
ARKG 19 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 60,646 0.0093
ARKG 18 Jul 2022 Buy ZY ZYMERGEN INC 69,145 0.0048
ARKG 18 Jul 2022 Buy TWST TWIST BIOSCIENCE CORP 15,906 0.0226
ARKG 18 Jul 2022 Buy SDGR SCHRODINGER INC 36,867 0.0407
ARKG 18 Jul 2022 Buy NRIX NURIX THERAPEUTICS INC 46,636 0.0247
ARKG 18 Jul 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 136,687 0.0140
ARKG 18 Jul 2022 Sell CGEN COMPUGEN LTD 13,245 0.0009
ARKG 18 Jul 2022 Buy ATAI ATAI LIFE SCIENCES NV 263,607 0.0385
ARKG 15 Jul 2022 Buy ZY ZYMERGEN INC 86,675 0.0058
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.